Targeting BRAF and MEK inhibitors in melanoma in the metastatic, neoadjuvant and adjuvant setting
Author:
Publisher
Ovid Technologies (Wolters Kluwer Health)
Subject
Cancer Research,Oncology
Reference19 articles.
1. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial;Hauschild;Lancet,2012
2. Vemurafenib in patients with BRAFV600 mutation-positive metastatic melanoma: final overall survival results of the randomized BRIM-3 study;Chapman;Ann Oncol,2017
3. Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma;Long;N Engl J Med,2014
4. Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial;Long;Lancet,2015
5. Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study;Long;Ann Oncol,2017
Cited by 10 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Incidental Cutaneous Melanoma;Journal of Brown Hospital Medicine;2024-07-01
2. Current State of Melanoma Therapy and Next Steps: Battling Therapeutic Resistance;Cancers;2024-04-19
3. Articles from 2022 to 2023 to Inform Your Cancer Practice: Melanoma;Annals of Surgical Oncology;2023-12-10
4. Overview of current melanoma therapies;Pigment Cell & Melanoma Research;2023-12-08
5. The molecular perspective on the melanoma and genome engineering of T-cells in targeting therapy;Environmental Research;2023-11
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3